...
首页> 外文期刊>BJU international >The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
【24h】

The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.

机译:摄入α-受体阻滞剂和5α-还原酶抑制剂对下尿路症状男性性健康的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE To assess the effect of tamsulosin on the Sexual Health Inventory for Men (SHIM) score in men diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). PATIENTS AND METHODS Analysis from the national database of a programme of the Prostate Cancer Educational Council identified 7974 men who completed the American Urologic Association Symptom Score (AUA-SS) and SHIM questionnaires. The patients were divided into three groups; group 1, men taking tamsulosin; group 2, men on other prescription medications for treating BPH symptoms; and group 3, men not currently taking any BPH medications. Linear regression was used to assess the association of tamsulosin and other alpha-blocker prescriptions for treating BPH symptoms with the decline in SHIM score. The interaction terms between AUA and the intake of tamsulosin was also adjusted for in the final analysis. RESULTS The median age of the men was 60 years. In groups 1, 2 and 3, (234, 291 and 7449 men, respectively)the mean (sd) AUA-SS was 13.0 (7.2), 12.1 (7.2) and 6.9 (5.8), and the mean SHIM scores 11.7 (6.8), 12.7 (6.5) and 15.9 (6.0), respectively. Adjusting for the AUA-SS, men in group 1 on tamsulosin had a significantly higher SHIM score with increasing AUA-SS score than men on other medications (P < 0.01), offsetting the negative correlation between the AUA-SS and SHIM (P < 0.01). Moreover, men in group 1 were more likely to have a higher AUA-SS and lower SHIM score than men in the other two groups, suggesting more severe symptoms in these men. CONCLUSIONS Men taking tamsulosin to treat LUTS appear to be at an advantage over men taking other alpha-blockers when the effect of LUTS on sexual health is considered. Furthermore, this effect was more profound in patients with more severe LUTS than those with mild and moderate symptoms. Future prospective trials are warranted to confirm this effect.
机译:目的评估坦洛新对男性良性前列腺增生(BPH)下尿路症状(LUTS)的男性性健康清单(SHIM)评分的影响。患者和方法从国家前列腺癌教育委员会计划的数据库中进行分析,确定了7974名完成了美国泌尿外科协会症状评分(AUA-SS)和SHIM问卷调查的男性。将患者分为三组。第一组,服用坦索罗辛的男人;第2组,使用其他处方药治疗BPH症状的男性;第三组,目前未服用任何BPH药物的男性。线性回归用于评估坦索罗辛和其他α-受体阻滞剂治疗BPH症状与SHIM评分下降之间的关系。在最终分析中还调整了AUA与坦洛新摄入之间的相互作用。结果男性的平均年龄为60岁。在第1、2和3组(分别为234、291和7449名男性)中,AUA-SS的平均(sd)为13.0(7.2),12.1(7.2)和6.9(5.8),SHIM平均得分为11.7(6.8) ),12.7(6.5)和15.9(6.0)。调整AUA-SS后,第1组服用坦洛新的男性的SHIM得分显着高于其他药物治疗的男性(P <0.01),而AUA-SS得分升高(P <0.01),从而抵消了AUA-SS与SHIM之间的负相关性(P <0.01)。 0.01)。此外,第1组的男性比其他两组的男性更有可能具有较高的AUA-SS和较低的SHIM评分,表明这些男性的症状更为严重。结论考虑到LUTS对性健康的影响,服用坦索罗辛治疗LUTS的男人似乎比服用其他α受体阻滞剂的男人更具优势。此外,与轻度和中度症状的患者相比,重度LUTS患者的这种作用更为明显。有必要进行进一步的前瞻性试验来证实这种作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号